# What Changed in the Teenagers' Bloodwork

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/what-changed-in-the-teenagers-bloodwork

> A STEP TEENS analysis found insulin resistance down 35%, liver enzymes down 18%, and lipids improved in 12-to-17-year-olds. All of it is bloodwork, and the outcomes it stands in for are decades away.

## Key points

- Insulin resistance −35.0% vs −5.3%; fasting insulin −33.6% vs −10.1%.
- ALT −17.9% vs −3.3%, the one marker mapping to a condition these teens may already have.
- All surrogate markers, in a group whose outcomes are forty years out.
- 'Bigger BMI reduction gave better results' is NOT a dose-response, because everyone in it got the drug.
- 2:1 randomization; only 64 on placebo. Secondary analysis of a trial powered for BMI.
- No long-term safety data in a growing body.

[The STEP TEENS trial](https://glpwatchdog.org/research/lists/top-glp1-adolescent-studies) established that semaglutide reduces BMI in adolescents. This follow-up analysis asked what else moved, and nearly everything measurable did. [Insulin resistance](https://glpwatchdog.org/research/glp1-and-insulin-resistance) fell 35%, liver enzymes fell 18%, and [cholesterol and triglycerides](https://glpwatchdog.org/research/glp1-and-cholesterol) improved.[1] All of it is bloodwork. In a fourteen-year-old, the outcomes those markers stand in for are four decades away. For the weight results themselves and what a parent should ask about them, see [GLP-1 drugs in teenagers](https://glpwatchdog.org/research/glp1-drugs-in-teenagers).

## What was found

The analysis covered 193 participants aged 12 to under 18 who had obesity but not type 2 diabetes. Over 68 weeks, 129 took weekly semaglutide 2.4 mg and 64 took placebo.

*Change from baseline at week 68, semaglutide 2.4 mg against placebo.[1]*

| Measure | Semaglutide | Placebo | P |
| --- | --- | --- | --- |
| Fasting serum insulin | −33.6% | −10.1% | 0.0012 |
| HOMA-IR (insulin resistance) | −35.0% | −5.3% | 0.0002 |
| ALT (liver enzyme) | −17.9% | −3.3% | 0.0232 |
| HbA1c | — | — | <0.0001 |
| Fasting plasma glucose | — | — | 0.0181 |
| Triglycerides | — | — | <0.0001 |
| LDL cholesterol | — | — | 0.0105 |
| Total cholesterol | — | — | <0.0001 |
| Waist-to-height ratio | — | — | <0.0001 |

## The liver result is the one that is not decades away

Most of that table describes risk accumulating toward events in middle age. ALT is different. Fatty liver disease is now the most common chronic liver condition in children, it is driven by exactly this metabolic picture, and elevated ALT is how it is usually first noticed.

So the 17.9% fall, against 3.3% on placebo, is not a stand-in for a distant outcome. It measures something a substantial share of these teenagers plausibly already had, and it is moving in the right direction now. Of everything in the analysis, this finding has the shortest distance between the number and a real condition.

## Why the rest needs holding lightly

> **These are surrogate markers, and in adolescents the surrogate is all there will ever be.** In an adult trial you can sometimes count heart attacks within the study. In a twelve-year-old, the events these markers predict fall decades after any trial anyone will run. That makes the surrogate unavoidable, and that is a reason for caution, not a reason to promote it to an outcome.

Markers moving the right way while patients do worse is a problem that has bitten cardiology more than once; it is set out in [a biomarker is not an outcome](https://glpwatchdog.org/research/a-biomarker-is-not-an-outcome). Nothing here suggests that is happening. But improved adolescent bloodwork is a promising sign, not a demonstrated reduction in lifetime disease.

Two structural caveats belong with the numbers. This is a secondary analysis of a trial designed and powered to measure BMI, so these endpoints are being asked of data collected for another purpose. And the randomization ran two-to-one, leaving only 64 people on placebo, which is a small comparison group for a nine-row table.

## One comparison in the paper that is not randomized

The analysis also reports that participants whose BMI fell by 20% or more had greater improvements than those whose BMI fell less. That reads like a dose-response relationship, which would strengthen the case considerably. It is not one.

> **Everyone in that comparison received the drug.** Splitting treated participants by how well they responded compares responders with non-responders, two groups that were never randomized against each other. Whatever makes someone lose more weight on semaglutide may independently improve their insulin sensitivity. The comparison cannot separate the two, and no analysis of it can.

It is a reasonable thing to report and an easy thing to over-read. A real dose-response analysis would compare randomly assigned doses, not self-selected outcomes.

## What is still unknown

- **Long-term safety in a growing body.** Sixty-eight weeks is the evidence base. Puberty, bone accrual and final adult height are not addressed by it.
- **What happens on stopping.** No one plans to take a medication indefinitely through adolescence without knowing that.
- **Whether any of these markers translate into fewer events**, which no trial in this age group can answer.
- **Effects on eating behavior and body image during adolescence**, which this analysis did not measure.

None of this argues against the drug in adolescents. It argues for describing what is known without making it sound bigger than it is.

## Frequently asked questions

### What did semaglutide change in adolescents beyond weight?

Over 68 weeks it reduced fasting insulin by 33.6% against 10.1% on placebo, insulin resistance by 35.0% against 5.3%, and the liver enzyme ALT by 17.9% against 3.3%, with improvements in HbA1c, fasting glucose, triglycerides, LDL and total cholesterol.

### Which finding matters most?

Arguably the ALT reduction. Fatty liver disease is the most common chronic liver condition in children and elevated ALT is how it is usually detected, so that number maps to something these teenagers may already have rather than to a risk decades away.

### Do these results mean fewer heart attacks later?

Unknown, and not answerable by any trial in this age group. These are surrogate markers, and the events they predict fall decades after any study anyone will run.

### The paper says bigger BMI reductions gave better results. Is that a dose-response?

No. Everyone in that comparison received the drug, so it compares people who responded well with people who did not, and those groups were never randomized against each other. Whatever causes a larger response may independently improve these markers.

### Is long-term safety established in teenagers?

No. The evidence base here is 68 weeks. Effects across puberty, on bone accrual and on final adult height are not addressed.

## References

1. Arslanian S, Gies I, Goldman B, et al. Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study. Diabetes Care. 2026. PMID: 41296499. https://pubmed.ncbi.nlm.nih.gov/41296499/

---

Cite as: GLP Watchdog, Nora Bissett, "What Changed in the Teenagers' Bloodwork", published 2026-08-20, updated 2026-10-27. https://glpwatchdog.org/research/what-changed-in-the-teenagers-bloodwork

Canonical HTML page: https://glpwatchdog.org/research/what-changed-in-the-teenagers-bloodwork

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
